一名白癜风患者使用2%克立硼罗软膏后的色素再生情况。 - Suppr

Suppr

超能文献

Repigmentation in a patient with vitiligo on crisaborole 2% ointment.

作者信息

Tam Idy, Kahn Jared S, Rosmarin David

机构信息

Tufts University School of Medicine, Boston, Massachusetts.

Department of Dermatology, Tufts Medical Center, Boston, Massachusetts.

出版信息

JAAD Case Rep. 2021 Mar 27;11:99-101. doi: 10.1016/j.jdcr.2021.03.028. eCollection 2021 May.

DOI:10.1016/j.jdcr.2021.03.028

PMID:33948468

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8079958/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da04/8079958/9adf76d7e79c/gr1.jpg

相似文献

Repigmentation in a patient with vitiligo on crisaborole 2% ointment.

JAAD Case Rep. 2021 Mar 27;11:99-101. doi: 10.1016/j.jdcr.2021.03.028. eCollection 2021 May.

Crisaborole Topical Ointment, 2%: A Nonsteroidal, Topical, Anti-Inflammatory Phosphodiesterase 4 Inhibitor in Clinical Development for the Treatment of Atopic Dermatitis.

J Drugs Dermatol. 2016 Apr;15(4):390-6.

Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults.

J Am Acad Dermatol. 2016 Sep;75(3):494-503.e6. doi: 10.1016/j.jaad.2016.05.046. Epub 2016 Jul 11.

Crisaborole Topical Ointment, 2% in Adults With Atopic Dermatitis: A Phase 2a, Vehicle-Controlled, Proof-of-Concept Study.

J Drugs Dermatol. 2015 Oct;14(10):1108-12.

Pharmacokinetic Profile, Safety, and Tolerability of Crisaborole Topical Ointment, 2% in Adolescents with Atopic Dermatitis: An Open-Label Phase 2a Study.

Pediatr Dermatol. 2016 Mar-Apr;33(2):150-9. doi: 10.1111/pde.12780. Epub 2016 Jan 18.

A Phase 2, Randomized, Controlled, Dose-Ranging Study Evaluating Crisaborole Topical Ointment, 0.5% and 2% in Adolescents With Mild to Moderate Atopic Dermatitis.

J Drugs Dermatol. 2015 Dec;14(12):1394-9.

Crisaborole Topical Ointment, 2% in Patients Ages 2 to 17 Years with Atopic Dermatitis: A Phase 1b, Open-Label, Maximal-Use Systemic Exposure Study.

Pediatr Dermatol. 2016 Jul;33(4):380-7. doi: 10.1111/pde.12872. Epub 2016 May 18.

Crisaborole Ointment 2%: A Review in Mild to Moderate Atopic Dermatitis.

Am J Clin Dermatol. 2017 Dec;18(6):837-843. doi: 10.1007/s40257-017-0327-4.

Crisaborole: Phosphodiesterase inhibitor for treatment of atopic dermatitis.

Drugs Today (Barc). 2017 Apr;53(4):239-245. doi: 10.1358/dot.2017.53.4.2604174.

Crisaborole and its potential role in treating atopic dermatitis: overview of early clinical studies.

Immunotherapy. 2016 Jul;8(8):853-66. doi: 10.2217/imt-2016-0023. Epub 2016 Jun 10.

引用本文的文献

Emerging Therapeutic Innovations for Vitiligo Treatment.

Curr Issues Mol Biol. 2025 Mar 14;47(3):191. doi: 10.3390/cimb47030191.

Recalcitrant Pediatric Facial Vitiligo Successfully Treated with Roflumilast Cream 0.3% Once Daily.

J Clin Aesthet Dermatol. 2025 Jan;18(1):52-54.

Vitiligo: From mechanisms of disease to treatable pathways.

Skin Health Dis. 2024 Sep 30;4(6):e460. doi: 10.1002/ski2.460. eCollection 2024 Dec.

Vitiligo: From Pathogenesis to Treatment.

J Clin Med. 2024 Sep 3;13(17):5225. doi: 10.3390/jcm13175225.

Up-and-Coming Drugs for the Treatment of Vitiligo.

Ann Dermatol. 2024 Aug;36(4):197-208. doi: 10.5021/ad.24.038.

本文引用的文献

Low dose oral corticosteroids, microneedling, and topical 5-fluorouracil: A novel treatment for recalcitrant pediatric vitiligo.

Pediatr Dermatol. 2021 Jan;38(1):322-323. doi: 10.1111/pde.14443. Epub 2020 Nov 10.

Apremilast in Combination with Narrowband UVB in the Treatment of Vitiligo: A 52-Week Monocentric Prospective Randomized Placebo-Controlled Study.

J Invest Dermatol. 2020 Aug;140(8):1533-1537.e2. doi: 10.1016/j.jid.2019.11.031. Epub 2020 Jan 29.

Apremilast is effective in controlling the progression of adult vitiligo: A case series.

Dermatol Ther. 2019 Jul;32(4):e12923. doi: 10.1111/dth.12923. Epub 2019 Apr 29.

Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases.

Front Pharmacol. 2018 Oct 17;9:1048. doi: 10.3389/fphar.2018.01048. eCollection 2018.

Keratinocyte-Derived Chemokines Orchestrate T-Cell Positioning in the Epidermis during Vitiligo and May Serve as Biomarkers of Disease.

J Invest Dermatol. 2017 Feb;137(2):350-358. doi: 10.1016/j.jid.2016.09.016. Epub 2016 Sep 26.

Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults.

J Am Acad Dermatol. 2016 Sep;75(3):494-503.e6. doi: 10.1016/j.jaad.2016.05.046. Epub 2016 Jul 11.

Dupilumab treatment in adults with moderate-to-severe atopic dermatitis.

N Engl J Med. 2014 Jul 10;371(2):130-9. doi: 10.1056/NEJMoa1314768.

Phosphodiesterase 4 inhibition in the treatment of psoriasis, psoriatic arthritis and other chronic inflammatory diseases.

Dermatol Ther (Heidelb). 2013 Apr 27;3(1):1-15. doi: 10.1007/s13555-013-0023-0. Print 2013 Jun.

Th17 cells and activated dendritic cells are increased in vitiligo lesions.

PLoS One. 2011 Apr 25;6(4):e18907. doi: 10.1371/journal.pone.0018907.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验